TP53 and hepatocellular carcinoma: D1 significantly inhibited HCC cell proliferation and clone formation by targeting the ubiquitin pathway, promoting YAP degradation, downregulating p53 and p21, arresting cells in S‐phase, and inducing apoptosis, demonstrating its potential for USP10‐positive HCC treatment.436